JOP20210317A1 - مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان - Google Patents

مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان

Info

Publication number
JOP20210317A1
JOP20210317A1 JOP/2021/0317A JOP20210317A JOP20210317A1 JO P20210317 A1 JOP20210317 A1 JO P20210317A1 JO P20210317 A JOP20210317 A JO P20210317A JO P20210317 A1 JOP20210317 A1 JO P20210317A1
Authority
JO
Jordan
Prior art keywords
mat2a
methods
treating cancer
inhibitors
compounds
Prior art date
Application number
JOP/2021/0317A
Other languages
English (en)
Inventor
Jeremy M Travins
Zhihua Sui
Mingzong Li
Samuel K Reznik
Zenon D Konteatis
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of JOP20210317A1 publication Critical patent/JOP20210317A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركبات لها الصيغة I، والصيغة II، وأملاحها المقبولة صيدليًا، مماثلات كيميائية، و/أو نظائر على النحو الموصوف في الكشف. تكون المركبات عبارةً عن مثبطات من صورة ميثيونين أدينوزيل ترانسفيراز المتماثلة 2A (MAT2A). كما يتعلق الاختراع الحالي بتوفير تركيبات صيدلية وطرق استخدام المركبات لعلاج سرطانات، بما في ذلك بعض السرطانات التي يتم فيها حذف الجين المرمِّز لميثيل ثيو أدينوزين فوسفوريلاز (MTAP).
JOP/2021/0317A 2019-05-31 2020-05-29 مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان JOP20210317A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855395P 2019-05-31 2019-05-31
PCT/US2020/035036 WO2020243376A1 (en) 2019-05-31 2020-05-29 Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Publications (1)

Publication Number Publication Date
JOP20210317A1 true JOP20210317A1 (ar) 2023-01-30

Family

ID=72179154

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0317A JOP20210317A1 (ar) 2019-05-31 2020-05-29 مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان

Country Status (16)

Country Link
US (1) US20220251081A1 (ar)
EP (1) EP3976611A1 (ar)
JP (1) JP2022534989A (ar)
AR (1) AR119046A1 (ar)
AU (1) AU2020284018A1 (ar)
BR (1) BR112021023825A2 (ar)
CA (1) CA3142340A1 (ar)
CO (1) CO2021017981A2 (ar)
CR (1) CR20210670A (ar)
IL (1) IL288395A (ar)
JO (1) JOP20210317A1 (ar)
MA (1) MA56050A (ar)
PE (1) PE20220387A1 (ar)
SG (1) SG11202112952SA (ar)
TW (1) TW202110841A (ar)
WO (1) WO2020243376A1 (ar)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3902803T (lt) * 2018-12-27 2023-04-25 Les Laboratoires Servier Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui
CN115960098B (zh) * 2020-09-11 2026-04-10 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
WO2022063128A1 (zh) * 2020-09-24 2022-03-31 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
CN114507231B (zh) * 2020-11-17 2025-06-03 南京再明医药有限公司 内酰胺类化合物及其制备方法
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc Gcn2 and perk kinase inhibitors and methods of use thereof
US20240124454A1 (en) * 2020-12-31 2024-04-18 Nanjing Zaiming Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
CN114874207A (zh) * 2021-02-05 2022-08-09 江苏先声药业有限公司 作为mat2a抑制剂的双环类化合物
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
JP2024516429A (ja) * 2021-04-30 2024-04-15 サイノハブ ファーマシューティカル カンパニー リミテッド メチオニンアデノシルトランスフェラーゼ阻害剤、その調製方法およびその適用
AR127404A1 (es) 2021-10-20 2024-01-17 Insilico Medicine Ip Ltd Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
PE20250609A1 (es) 2021-12-03 2025-02-26 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos
CN118414338A (zh) * 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
JP2025503186A (ja) * 2022-01-26 2025-01-30 勤浩医▲葯▼（▲蘇▼州）有限公司 Ｍｔａｐ欠失型がん治療用メチオニンアデノシルトランスフェラーゼ２ａ阻害剤
WO2023169554A1 (zh) * 2022-03-11 2023-09-14 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
JP2025521737A (ja) 2022-06-27 2025-07-10 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 三環式化合物およびその使用
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
AU2023361063A1 (en) * 2022-10-13 2025-04-17 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
CN117645598A (zh) * 2023-02-16 2024-03-05 武汉誉祥医药科技有限公司 氮杂二并多元稠环化合物及其药物组合物和应用
CN116239541B (zh) * 2023-05-11 2023-07-21 英矽智能科技(上海)有限公司 N-苯基-2-氧代喹唑啉类化合物及其应用
CN121586715A (zh) * 2023-06-14 2026-02-27 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法
WO2025152991A1 (zh) * 2024-01-15 2025-07-24 江苏威凯尔医药科技股份有限公司 一种mat2a抑制剂及其用途
CN120398878A (zh) * 2024-02-01 2025-08-01 艾立康药业股份有限公司 一种吡啶并吡啶酮类mat2a抑制剂及其药物组合物、医药用途
CN118724899B (zh) * 2024-07-03 2025-09-30 中国药科大学 2(1h)-喹喔啉酮化合物、其药物组合物及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
CA2420286A1 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
JP5478488B2 (ja) 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション Ｊａｎｕｓキナーゼの阻害剤
US11524960B2 (en) * 2018-03-30 2022-12-13 Servier Pharmaceuticals Llc Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer

Also Published As

Publication number Publication date
CR20210670A (es) 2022-02-11
WO2020243376A1 (en) 2020-12-03
TW202110841A (zh) 2021-03-16
PE20220387A1 (es) 2022-03-18
US20220251081A1 (en) 2022-08-11
AU2020284018A1 (en) 2022-01-27
CA3142340A1 (en) 2020-12-03
AR119046A1 (es) 2021-11-17
EP3976611A1 (en) 2022-04-06
BR112021023825A2 (pt) 2022-02-08
SG11202112952SA (en) 2021-12-30
MA56050A (fr) 2022-04-06
JP2022534989A (ja) 2022-08-04
IL288395A (en) 2022-01-01
CO2021017981A2 (es) 2022-04-19

Similar Documents

Publication Publication Date Title
CR20210670A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
SA521422405B1 (ar) Mat2a مثبطات أزا-غير متجانسة ثنائية الحلقة لـ وطرق الاستخدام لعلاج السرطان
PH12021551493A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12020551507A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12021551274A1 (en) 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
ZA202102999B (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
CR20200441A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
PH12022550470A1 (en) Triazolopyrimidines as a2a / a2b inhibitors
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
MX2025002407A (es) Inhibidores de egfr y sus usos
ZA202005603B (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer